Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.50 |
| ▸ | ITGAV | P06756 | 7/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | CTSA | P10619 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9467735 | 0.85 | L3MBTL1 (0.51) | L3MBTL1TBXAS1SMN1; SMN2KCNA5LMNA | |
| SCHEMBL12883291 | 0.85 | L3MBTL1 (0.51) | L3MBTL1TBXAS1SMN1; SMN2KCNA5NAPRT | |
| SCHEMBL2370434 | 0.85 | L3MBTL1 (0.51) | L3MBTL1TBXAS1SMN1; SMN2KCNA5NAPRT | |
| SCHEMBL15592461 | 0.83 | ITGB3 (0.51) | L3MBTL1ITGB3ITGAVTBXAS1ITGA2B | |
| SCHEMBL9519691 | 0.83 | L3MBTL1 (0.50) | L3MBTL1ITGB3ITGAVTBXAS1ITGA2B | |
| SCHEMBL25152114 | 0.83 | ITGB3 (0.51) | L3MBTL1ITGB3ITGAVTBXAS1ITGA2B | |
| SCHEMBL27497417 | 0.83 | TBXAS1 (0.58) | L3MBTL1TBXAS1SMN1; SMN2 | |
| SCHEMBL5856512 | 0.82 | TBXAS1 (0.53) | ITGB3ITGAVTBXAS1ITGA2BSMN1; SMN2 | |
| SCHEMBL23685636 | 0.82 | L3MBTL1 (0.59) | L3MBTL1ITGB3ITGAVSMN1; SMN2KCNA5 | |
| SCHEMBL23685640 | 0.82 | L3MBTL1 (0.59) | L3MBTL1ITGB3ITGAVSMN1; SMN2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| CN-1505626-A | Novel benzylpiperidine compound | ������ҩ��ʽ���� | 2004-06-16 | — | — | CN | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| US-4649141-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-03-10 | — | — | US | disclosed |
| US-4539207-A | Pyrimidine compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-09-03 | — | — | US | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | L3MBTL1 2017/4885ITGB3 4428/4885ITGAV 4536/4885 |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | L3MBTL1 1853/4885ITGB3 3651/4885ITGAV 4677/4885 |
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | L3MBTL1 1169/4885ITGB3 4171/4885ITGAV 4424/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | L3MBTL1 2559/4885ITGB3 4316/4885ITGAV 3962/4885 |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | L3MBTL1 3984/4885ITGB3 1498/4885ITGAV 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.